As a pan-cancer MES marker, AXL upregulation can be observed after treatment with targeted therapy.63 Thus, combination strategies with AXL-targeted ADCs aim to prevent resistance by targeting therapy-induced heterogeneity.77 In experimental neuroblastoma models, AXL has been reported to contribute to therapy resistance to ALK inhibitors.62 Future studies evaluating various treatment schedules of ADCT-601 in additional MES-dominant models will be essential to further determine the efficacy of this compound. This evidence concerns the gene AXL and cancer.